Exploring the molecular mechanism of Suoquan pill in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, in vitro experiment

被引:0
|
作者
Yan, Zi-Jie [1 ]
Kang, Yu [2 ]
Liu, Shu-Man [1 ]
Wang, Fang-Yu [3 ]
Xiao, Man [4 ]
Xie, Yi-Qiang [1 ]
机构
[1] Hainan Med Univ, Coll Tradit Chinese Med, 4 Xue Yuan Rd, Haikou 571199, Peoples R China
[2] Heilongjiang Acad Tradit Chinese Med, Grad Sch, Harbin 150001, Peoples R China
[3] Hainan Med Univ, Coll Pharm, Dept Pharmacol, Haikou 571199, Peoples R China
[4] Hainan Med Univ, Key Lab Biochem & Mol Biol, 4 Xue Yuan Rd, Haikou 571199, Peoples R China
来源
TRADITIONAL MEDICINE RESEARCH | 2024年 / 9卷 / 11期
基金
中国国家自然科学基金;
关键词
traditional Chinese medicine; diabetic kidney disease; Suoquan pill; network analysis; molecular docking; PLATELET-ACTIVATING-FACTOR; MESANGIAL CELLS; NEPHROPATHY; SRC; INHIBITION; PROGRESSION; PATHWAY; FAMILY; SLOWS;
D O I
10.53388/TMR20240105002
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Diabetic kidney disease (DKD) is a microvascular complication of diabetes mellitus and is the main cause of end-stage renal failure. Suoquan pills (SQP) has a variety of pharmacological activities and multiple therapeutic effects, and it is used clinically as a basic formula for the treatment of DKD. Methods: Public databases were used to identify SQP compounds and the potential targets of SQP and DKD. A drug-component-therapeutic target network was constructed. Protein-protein interaction network analysis, Gene Ontology functional analysis, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were used to analyse the potential molecular mechanisms of SQP based on common targets of drugs and diseases. Molecular docking simulations were conducted to confirm the binding abity of the core compounds to key targets. The efficacy and predicted molecular mechanisms of SQP were validated using cell counting kit-8 assay, flow cytometry, and western blotting with HK-2 cells as a model. Results: Network pharmacology analysis showed that 26 compounds and 207 potential targets of SQP were involved in the treatment of DKD; boldine, denudatin B, pinocembrin, kaempferoid, and quercetin were considered core compounds, and epidermal growth factor receptor (EGFR) and proto-oncogene, non-receptor tyrosine kinase (SRC) were considered key targets. Gene Ontology enrichment analysis indicated that protein phosphorylation and negative regulation of apoptotic processes are important biological processes in the treatment of DKD by SQP. Molecular docking confirmed the excellent binding abilities of boldine, denudatin B, kaempferide, and quercetin to EGFR and SRC. The results of in vitro experiments showed that treatment with an ethanolic extract of SQP significantly protected HK-2 cells from high glucose-induced cell damage. In addition, the SQP ethanol extract inhibited the phosphorylation of EGFR and SRC, suppressed the apoptosis rate, and regulated apoptosis-related proteins in HK-2 cells under high glucose stress. Conclusion: This study systematically and intuitively illustrated the possible pharmacological mechanisms of SQP against DKD through multiple components, targets, and signalling pathways, especially the inhibition of EGFR and SRC phosphorylation and apoptosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Mechanism of Huaiqihuang in treatment of diabetic kidney disease based on network pharmacology, molecular docking and in vitro experiment
    Wang, Junwei
    Ma, Guiqiao
    Zhang, Peipei
    Ma, Chaojing
    Shao, Jing
    Wang, Liping
    Ma, Chanjuan
    MEDICINE, 2023, 102 (50) : E36177
  • [2] Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation
    Chen, Shengnan
    Li, Bo
    Chen, Lei
    Jiang, Hongli
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [3] The molecular mechanism of "Dahuang-Shengjiang-Banxia decoction" in the treatment of diabetic kidney disease was verified based on network pharmacology and molecular docking
    Xu, Duojie
    Yuan, Ling
    Che, Mengying
    Liu, Wenjing
    Li, Xiangyang
    Yang, Yifan
    Wang, Kaili
    Nan, Yi
    HELIYON, 2024, 10 (02)
  • [4] Exploring the mechanism of Tingli Pill in the treatment of HFpEF based on network pharmacology and molecular docking
    Chi, Kuo
    Yang, Saisai
    Zhang, Yao
    Zhao, Yongfa
    Zhao, Jiahe
    Chen, Qiuhan
    Ge, Yuan
    Liu, Jing
    MEDICINE, 2024, 103 (16) : E37727
  • [5] Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation
    Shengnan Chen
    Bo Li
    Lei Chen
    Hongli Jiang
    Journal of Translational Medicine, 21
  • [6] Exploring the mechanism of hirudin in the treatment of diabetic kidney disease using network pharmacology combined with molecular docking verification
    Pang Xinxin
    Zhu Qing
    Peng Zining
    Zhang Yage
    Shi Xiujie
    Han Jiarui
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2022, 42 (04) : 586 - 594
  • [7] Molecular mechanism of action of Liuwei Dihuang pill for the treatment of osteoporosis based on network pharmacology and molecular docking
    Feng, Peng
    Che, Ying
    Chen, De-Qiang
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2020, 33
  • [8] Exploring the pharmacological mechanisms of Tripterygium wilfordii against diabetic kidney disease using network pharmacology and molecular docking
    Lu, Meiqi
    Ou, Juanjuan
    Deng, Xiaoqi
    Chen, Yixuan
    Gao, Qing
    HELIYON, 2023, 9 (06)
  • [9] Potential Molecular Mechanism of Yishen Capsule in the Treatment of Diabetic Nephropathy Based on Network Pharmacology and Molecular Docking
    Hu, Yaling
    Liu, Shuang
    Liu, Wenyuan
    Zhang, Ziyuan
    Liu, Yuxiang
    Li, Sufen
    Sun, Dalin
    Zhang, Guang
    Fang, Jingai
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2022, 15 : 943 - 962
  • [10] Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking
    He, Qingmin
    Liu, Chuan
    Wang, Xiaohan
    Rong, Kang
    Zhu, Mingyang
    Duan, Liying
    Zheng, Pengyuan
    Mi, Yang
    FRONTIERS IN PHARMACOLOGY, 2023, 14